Ontology highlight
ABSTRACT:
SUBMITTER: Rerks-Ngarm S
PROVIDER: S-EPMC5853427 | biostudies-literature | 2017 Apr
REPOSITORIES: biostudies-literature
Rerks-Ngarm Supachai S Pitisuttithum Punnee P Excler Jean-Louis JL Nitayaphan Sorachai S Kaewkungwal Jaranit J Premsri Nakorn N Kunasol Prayura P Karasavvas Nicos N Schuetz Alexandra A Ngauy Viseth V Sinangil Faruk F Dawson Peter P deCamp Allan C AC Phogat Sanjay S Garunathan Sanjay S Tartaglia James J DiazGranados Carlos C Ratto-Kim Silvia S Pegu Poonam P Eller Michael M Karnasuta Chitraporn C Montefiori David C DC Sawant Sheetal S Vandergrift Nathan N Wills Saintedym S Tomaras Georgia D GD Robb Merlin L ML Michael Nelson L NL Kim Jerome H JH Vasan Sandhya S O'Connell Robert J RJ
The Journal of infectious diseases 20170401 8
<h4>Background</h4>The RV144 ALVAC-HIV prime, AIDSVAX B/E boost afforded 60% efficacy against human immunodeficiency virus (HIV) acquisition at 1 year, waning to 31.2% after 3.5 years. We hypothesized that additional vaccinations might augment immune correlates of protection.<h4>Methods</h4>In a randomized placebo-controlled double-blind study of 162 HIV-negative RV144 vaccine recipients, we evaluated 2 additional boosts, given 6-8 years since RV144 vaccination, for safety and immunogenicity, at ...[more]